January 15th 2022
By Tony Hagen
The International Generic and Biosimilar Medicines Association has appointed a veteran member, Vivian Frittelli, MBA, ACIS, to take over as chair.
January 11th 2022
By Meir Rinde, MS
In a recent paper, Sarfaraz K. Niazi, PhD summarizes some of his central ideas on the relevance of FDA biosimilar testing standards.
January 6th 2022
Biobetters may gain an edge on reference products, and multiple biosimilars are under development for ophthalmic disorders, the authors write.
January 1st 2022
Biosimilars have produced more than $20 billion of savings in Europe, but more use of these agents is needed.
December 24th 2021
With fewer of the risks associated with novel drug development, biosimilar candidates allow manufacturers to plan far into the future for marketing needs.
December 21st 2021
The year 2021 brought several firsts in biosimilars and set the stage for expansion across therapeutic areas including diabetes and ophthalmology.
December 16th 2021
Investigators said more evidence would help to convince clinicians of the safety of switching between biosimilar products.
December 15th 2021
Xbrane Biopharma of Stockholm, Sweden, said its next biosimilar candidates will target the demand for oncology and hematology therapeutics.
December 6th 2021
Henlius gains approval in China for Hanbeitai and officials discuss combination therapy options with experimental therapy serplulimab and ophthalmology treatment.
December 2nd 2021
Researchers report findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.
